This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishikawa, M. Articles by Nagawa, H. Search for Related Content PubMed PubMed Citation Articles by Ishikawa, M. Articles by Nagawa, H.

Plasma Adiponectin and Gastric Cancer

¹ Department of Surgery, Division of Surgical Oncology, University of Tokyo, Bunkyo-ku, Tokyo, Japan and ² Department of Surgery, Yaizu Municipal Hospital, Yaizu-City, Shizuoka, Japan

Requests for reprints: Makoto Ishikawa, Department of Surgical Oncology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-3815-5411, ext. 33246; Fax: 81-3-3811-6822; E-mail: makoto-ishi{at}umin.ac.jp.

Background: Recently, increased body weight has been associated with an increased risk of cancers at multiple specific sites, including gastric cancer. Adiponectin is a peptide hormone secreted by adipose tissue, affecting the proliferation and insulin sensitivity of various types of cells. Moreover, the circulating level of adiponectin has been reported to be inversely related to body mass index.

Methods: Fasting plasma levels of adiponectin were determined in 75 patients with gastric cancer and 52 healthy controls using an ELISA. In these patients, we analyzed the association between plasma adiponectin level and gastric cancer risk as well as various clinicopathologic characteristics.

Results: Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 ± 6.2 versus 13.3 ± 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different. In addition, adiponectin level was extremely low in patients with upper gastric cancers (upper, 5.5 ± 4.1 ng/mL; middle, 9.7 ± 6.4 ng/mL; lower, 10.7 ± 4.1 ng/mL; P = 0.012). Furthermore, adiponectin level tended to decrease as the tumor stage increased (stage I, 9.9 ± 6.9 ng/mL; stage II, 8.7 ± 5.5 ng/mL; stage III, 8.6 ± 4.1 ng/mL; stage IV, 5.2 ± 6.2 ng/mL; P = 0.34). Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer.

Conclusions: Our results suggest that a low plasma adiponectin level is associated with an increased risk for gastric cancer and raise the possibility that adiponectin has a potential role in the progression of gastric cancer, especially in undifferentiated type cancers in the upper stomach.

Key Words: gastric cancer • plasma adiponectin • obesity

This article has been cited by other articles:

				B J Kendall, G A Macdonald, N K Hayward, J B Prins, I Brown, N Walker, N Pandeya, A C Green, P M Webb, D C Whiteman, et al. Leptin and the risk of Barrett's oesophagus Gut, April 1, 2008; 57(4): 448 - 454. [Abstract] [Full Text] [PDF]

				A. Horiguchi, K. Ito, M. Sumitomo, F. Kimura, T. Asano, and M. Hayakawa Decreased Serum Adiponectin Levels in Patients with Metastatic Renal Cell Carcinoma Jpn. J. Clin. Oncol., February 1, 2008; 38(2): 106 - 111. [Abstract] [Full Text] [PDF]

				D Barb, A Neuwirth, C S Mantzoros, and S P Balk Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway Endocr. Relat. Cancer, December 1, 2007; 14(4): 995 - 1005. [Abstract] [Full Text] [PDF]

				D. Barb, C. J Williams, A. K Neuwirth, and C. S Mantzoros Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 858S - 866S. [Abstract] [Full Text] [PDF]

				G. A. Laughlin, E. Barrett-Connor, S. May, and C. Langenberg Association of Adiponectin with Coronary Heart Disease and Mortality: The Rancho Bernardo Study Am. J. Epidemiol., January 15, 2007; 165(2): 164 - 174. [Abstract] [Full Text] [PDF]

				Y. Wang, J. B. Lam, K. S.L. Lam, J. Liu, M. C. Lam, R. L.C. Hoo, D. Wu, G. J.S. Cooper, and A. Xu Adiponectin Modulates the Glycogen Synthase Kinase-3{beta}/{beta}-Catenin Signaling Pathway and Attenuates Mammary Tumorigenesis of MDA-MB-231 Cells in Nude Mice Cancer Res., December 1, 2006; 66(23): 11462 - 11470. [Abstract] [Full Text] [PDF]

				S. Cowey and R. W. Hardy The Metabolic Syndrome: A High-Risk State for Cancer? Am. J. Pathol., November 1, 2006; 169(5): 1505 - 1522. [Abstract] [Full Text] [PDF]

				H. Motoshima, B. J. Goldstein, M. Igata, and E. Araki AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer J. Physiol., July 1, 2006; 574(1): 63 - 71. [Abstract] [Full Text] [PDF]

				E. K. Wei, E. Giovannucci, C. S. Fuchs, W. C. Willett, and C. S. Mantzoros Low Plasma Adiponectin Levels and Risk of Colorectal Cancer in Men: A Prospective Study J Natl Cancer Inst, November 16, 2005; 97(22): 1688 - 1694. [Abstract] [Full Text] [PDF]